Psychiatry · Antipsychotic
The FDA's approval of Torrent's ANDA208055 for Lurasidone Hydrochloride presents a significant competitive challenge in the antipsychotic market. This could lead to pricing pressures and shifts in market share among established players, necessitating strategic reassessment.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/26/2026, 6:32:14 AM
Assessment confidence: 80% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Torrent's ANDA208055 for Lurasidone Hydrochloride presents a significant competitive challenge in the antipsychotic market. This could lead to pricing pressures and shifts in market share among established players, necessitating strategic reassessment. Regulatory context from FDA (FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (14 high-relevance).
Strategic teams should assess the potential market entry of Torrent's Lurasidone Hydrochloride and its implications for pricing and market share. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Psychiatry · Antipsychotic, 8 regulatory and 3 competitive items passed relevance filtering for Torrent Pharmaceuticals.
The most relevant competitive pressure comes from FDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride) (Humanexa Signals) — sponsor/company relevance (novartis). Secondary pressure from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy. This approval status may enable Torrent to compete more effectively in the antipsychotic market, potentially impacting existing players.
Regulatory risk is concentrated around FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (lurasidone hydrochloride); Regulatory pathway relevance (nda). The approval status indicates compliance with regulatory requirements, but does not suggest immediate changes to existing regulations or approvals for other products.
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (lurasidone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — MOXIFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — CIPROFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — CIPROFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceThe Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceRelationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceA Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceMenstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNeurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride)
Humanexa Signalshigh relevance
Sponsor/company relevance (Novartis)
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Torrent's ANDA208055 for Lurasidone Hydrochloride presents a significant competitive challenge in the antipsychotic market. This could lead to pricing pressures and shifts in market share among established players, necessitating strategic reassessment.
The entry of Torrent's product may disrupt pricing strategies and market dynamics, potentially affecting revenue streams for current market leaders.
The approval status indicates compliance with regulatory requirements, but does not suggest immediate changes to existing regulations or approvals for other products.
Monitor the timeline for market launch and any subsequent competitive responses from established antipsychotic manufacturers.
Track for follow-up milestones; no immediate action required.